These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1407993)

  • 1. Effects of pilocarpine on salivary flow in patients with Sjogren's syndrome.
    Fox PC; Mandel ID
    Oral Surg Oral Med Oral Pathol; 1992 Sep; 74(3):315-8. PubMed ID: 1407993
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral pilocarpine HCl stimulates labial (minor) salivary gland flow in patients with Sjögren's syndrome.
    Rhodus NL
    Oral Dis; 1997 Jun; 3(2):93-8. PubMed ID: 9467349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of long-term pilocarpine due to increased muscarinic acetylcholine receptor 3 in salivary glands.
    Minagi HO; Ikai K; Araie T; Sakai M; Sakai T
    Biochem Biophys Res Commun; 2018 Sep; 503(2):1098-1102. PubMed ID: 29953856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pilocarpine on salivary flow in patients with Sjögren's syndrome.
    Rhodus NL; Schuh MJ
    Oral Surg Oral Med Oral Pathol; 1991 Nov; 72(5):545-9. PubMed ID: 1745512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren's syndrome.
    Tomiita M; Takei S; Kuwada N; Nonaka Y; Saito K; Shimojo N; Kohno Y
    Mod Rheumatol; 2010 Oct; 20(5):486-90. PubMed ID: 20517630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjögren's syndrome. The MGI PHARMA Sjögren's Syndrome Study Group.
    Nelson JD; Friedlaender M; Yeatts RP; Yee R; McDermott M; Orlin S; Gallagher SC; Shrotriya RC
    Adv Exp Med Biol; 1998; 438():979-83. PubMed ID: 9634998
    [No Abstract]   [Full Text] [Related]  

  • 7. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome.
    Iwabuchi Y; Masuhara T
    Gen Pharmacol; 1994 Jan; 25(1):123-9. PubMed ID: 7517901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Pilocarpine on impaired salivary secretion in patients with Sjögren's syndrome.
    Jorkjend L; Bergenholtz A; Johansson AK; Johansson A
    Swed Dent J; 2008; 32(2):49-56. PubMed ID: 18700333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dry mouth symptoms of Sjögren's syndrome.
    Dent Assist; 2000; 69(5):22-3. PubMed ID: 11218474
    [No Abstract]   [Full Text] [Related]  

  • 10. A controlled release pilocarpine buccal insert in the treatment of Sjögren's syndrome.
    Gibson J; Halliday JA; Ewert K; Robertson S
    Br Dent J; 2007 Apr; 202(7):E17; discussion 404-5. PubMed ID: 17273177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study.
    Rhodus NL; Liljemark W; Bloomquist C; Bereuter J
    Quintessence Int; 1998 Nov; 29(11):705-10. PubMed ID: 10200720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögrens syndrome.
    Papas AS; Fernandez MM; Castano RA; Gallagher SC; Trivedi M; Shrotriya RC
    Adv Exp Med Biol; 1998; 438():973-8. PubMed ID: 9634997
    [No Abstract]   [Full Text] [Related]  

  • 13. Lamivudine is not effective in primary Sjögren's syndrome.
    Gescuk B; Wu AJ; Whitcher JP; Daniels TE; Lund S; Fye K; Davis JC
    Ann Rheum Dis; 2005 Sep; 64(9):1326-30. PubMed ID: 15708886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination of rituximab with combined pulse-therapy with high doses of methylprednisolone and cyclophosphamide: effects on immunomorphological and functional disturbances of the salivary glands in a patient with Sjogren's disease and MALT-lymphoma].
    Vasil'ev VI; Kokosadze NV; Logvinenko OA; Nikitin EA; Mitrikov BV; Rodionova EB; Varlamova EIu
    Ter Arkh; 2008; 80(5):76-9. PubMed ID: 18590121
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of muscarinic agonists in the treatment of Sjögren's syndrome.
    Fox RI; Konttinen Y; Fisher A
    Clin Immunol; 2001 Dec; 101(3):249-63. PubMed ID: 11726216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of the treatment with oral pilocarpine in 100 patients with primary Sjögrens syndrome].
    Brito-Zerón P; Ramos-Casals M; Nardi N; Font J
    Med Clin (Barc); 2006 Apr; 126(16):637. PubMed ID: 16759558
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of xerostomic medications on stimulated salivary flow rate in patients with Sjögren's syndrome.
    Simmons DD; Al-Hashimi I; Haghighat N
    Quintessence Int; 2000 Mar; 31(3):196-200. PubMed ID: 11203926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren's syndrome.
    Garlapati K; Kammari A; Badam RK; B E S; Boringi M; Soni P
    Immunopharmacol Immunotoxicol; 2019 Apr; 41(2):312-318. PubMed ID: 30932714
    [No Abstract]   [Full Text] [Related]  

  • 19. Progression of salivary gland dysfunction in patients with Sjogren's syndrome.
    Pijpe J; Kalk WW; Bootsma H; Spijkervet FK; Kallenberg CG; Vissink A
    Ann Rheum Dis; 2007 Jan; 66(1):107-12. PubMed ID: 16728458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapy of Sjogren's syndrome: a review.
    Coaccioli S; Giuliani M; Puxeddu A
    Clin Ter; 2007; 158(5):453-6. PubMed ID: 18062353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.